Hercules Capital, Inc. is a business development company that specializes in providing private equity, venture debt, and growth capital to privately held, venture capital-backed companies at all stages of development, from mid venture to expansion stage. It also serves select publicly listed companies and special opportunity companies that need additional capital for acquisitions, recapitalizations, and refinancing, as well as established-stage companies. The firm offers a range of financing solutions, including growth capital, management buy-outs, corporate spin-outs, asset-based financing, bridge financing to IPO or M&A, and customized financing. It invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments, generally in companies that have been operating for at least six to 12 months prior to investment, with a preference for technology, SaaS Finance, energy technology, and sustainable industries.
Hercules Capital Appoints Alfred B. Fichera to Board of Directors
Hercules Capital, Inc. announced that Alfred B. Fichera was appointed as an independent member of its board of directors, effective September 17, 2026. Fichera, an audit and accounting professional with more than 40 years across the financial services and asset management industries, will serve on the Company's Audit Committee. He served in various capacities at KPMG LLP from 1982 until his retirement in 2019, including as Global Head of Alternative Investments, National Asset Management Leader, National Partner-in-Charge of Alternative Investments, and as an Audit Partner for nearly 25 years. Since September 2025, Fichera has served as an independent director and chair of the audit committee of Warburg Pincus Access Fund, L.P. Hercules Capital is the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by leading venture capital and select private equity firms.
Hercules Capital Slips 1.25% as Analysts Eye $0.49 Quarterly EPS
Hercules Capital closed the latest session at $17.39, down 1.25% on the day, a steeper decline than the S&P 500's 0.59% loss, while the Dow fell 0.6% and the Nasdaq dropped 0.65%. Over the past month the specialty finance company gained 6.08%, outpacing the Finance sector and the S&P 500, which each lost 1.37%. Ahead of its upcoming earnings disclosure, analysts expect Hercules Capital to post earnings of $0.49 per share, flat versus the year-ago period, on quarterly revenue of $142.2 million, up 2.98% from a year earlier. For the full year, the Zacks Consensus Estimates call for earnings of $1.95 per share and revenue of $578.1 million, changes of +2.09% and +8.56% respectively from last year. Hercules Capital currently carries a Zacks Rank of #3 (Hold) and trades at a Forward P/E ratio of 9.03, a premium to its industry's average Forward P/E of 8.12.
Hercules Capital Reports Record Q2 Results, Raises Dividend, and Completes $321 Million Note Offering
Hercules Capital reported record second-quarter 2026 results, with revenue rising to US$149.11 million and net income to US$130.18 million, alongside higher earnings per share from continuing operations compared to a year earlier. The company increased its regular quarterly dividend to US$0.47 per share, declared a US$0.07 supplemental distribution, and recently completed a US$321.27 million fixed-income offering of 6.300% senior unsecured notes due 2031. These moves underscore the firm's balance sheet flexibility and shareholder payout capacity following strong investment income. The results highlight the venture lending model's reliance on healthy origination activity and disciplined credit standards, though risks from competition and sector concentration in tech and life sciences remain.
Hercules Capital Q2 beat refocuses valuation narrative
Hercules Capital reported record second-quarter 2026 originations, investment income, and net investment income, alongside higher revenue and net income, with early loan repayments running ahead of guidance. Management highlighted steady portfolio credit quality, strong liquidity, and ongoing contributions from the private credit business. The stock rose 3.01% on the day of the release and 4.39% over the following week, though it remains down 12.94% year to date. The most followed narrative pegs fair value at $19.36 against a last close of $16.42, implying a 15.2% undervaluation, driven by compounding earnings, resilient margins, and a richer future earnings multiple, while noting risks from competition and early prepayments.
Hercules Capital Prices $325 Million Institutional Notes Offering at 6.300%
Hercules Capital has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031. The unsecured notes bear interest at 6.300% per year, payable semiannually, mature on July 24, 2031, and may be redeemed at par plus a make-whole premium. The company intends to use the net proceeds to repay outstanding indebtedness, fund investments, and for general corporate purposes. Goldman Sachs & Co. LLC, SMBC Nikko Securities America, Inc., and MUFG Securities Americas Inc. are acting as joint book-running managers, with several co-managers also participating. The closing is expected on July 24, 2026, subject to customary conditions.
TD Cowen Initiates Dyne Therapeutics With Buy Rating on Force Platform Potential
TD Cowen initiated coverage of Dyne Therapeutics with a Buy rating on June 26, citing the potential of its Force platform to improve drug delivery in neuromuscular and CNS diseases. The firm highlighted late-stage candidates z-basivarsen for myotonic dystrophy type 1 and z-rostudirsen for exon 51 Duchenne muscular dystrophy mutations as potential top-tier therapies. Separately, Dyne amended its non-dilutive senior secured term loan with Hercules Capital on June 17, receiving $50 million at closing and gaining the option to draw an additional $50 million tranche upon achieving certain milestones, while the final facility was expanded by $25 million to provide up to $125 million in capital at Hercules' discretion.
Lexicon Pharmaceuticals Gains Over 15% on Russell 3000 Inclusion and Strong Q1 Earnings
Lexicon Pharmaceuticals has gained more than 15% over the past month, driven by its inclusion in the Russell 3000 index and strong fiscal first quarter 2026 earnings. The company posted $21.1 million in revenue, far exceeding expectations of $9.78 million, with revenue growing 1,523% year-over-year, boosted by $20 million in development milestones from the Novo Nordisk licensing agreement for the LX9851 obesity program. Liquidity strengthened with a new $100 million loan facility from Hercules Capital, with an initial $55 million funded to support operations for at least the next 12 months. Management highlighted strong progress for the SONATA-HCM Phase 3 trial and plans to resubmit the ZYNQUISTA New Drug Application for type 1 diabetes by mid-2026. Citi raised its price target on the stock to $3.10 from $2.30 and maintained a Buy rating.
4DMT Secures Up to $200 Million Credit Facility from Hercules Capital
4D Molecular Therapeutics has entered into a strategic credit facility agreement with Hercules Capital for up to $200 million. The company drew an initial $20 million at closing, with an additional $30 million available at its option through June 15, 2027, another $100 million upon achieving certain milestones, and the remaining $50 million subject to final lender approval. As of March 31, 2026, 4DMT held $458 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028. The non-dilutive financing is intended to support the Phase 3 development and pre-commercial planning of its lead gene therapy candidate 4D-150 for wet age-related macular degeneration and diabetic macular edema.
Hercules Capital Stock Drops 16.9% in Six Months Amid EPS and Debt Concerns
Hercules Capital's stock price fell to $15.30 over the past six months, a 16.9% decline that contrasts with the S&P 500's 8.5% gain. The company's earnings per share grew at an 8% compounded annual rate over five years, lagging its 14.4% annualized revenue growth and indicating declining per-share profitability. Hercules Capital also carries $2.54 billion in debt against $44.93 million in cash, resulting in a net-debt-to-EBITDA ratio of 6.8 times based on $368 million in trailing twelve-month EBITDA, which raises concerns about financial flexibility. The stock trades at 7.9 times forward earnings, but analysts caution that shaky fundamentals could pose downside risk.
Dyne Therapeutics expands debt facility with Hercules Capital to up to $400 million
Dyne Therapeutics has amended its senior secured term loan facility with Hercules Capital, increasing total borrowing capacity to up to $400 million. The amendment provides an additional $125 million in potential funding, with $50 million drawn immediately at closing. A new $50 million tranche is available at Dyne's option upon achieving certain milestones, and the final tranche was increased by $25 million to up to $75 million, fundable at Dyne's request and Hercules' discretion. Including the $50 million just funded, Dyne has borrowed $200 million across three tranches and retains access to up to $200 million in future funding. The company plans to use the capital to advance its lead candidates, zeleciment rostudirsen for Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1, toward potential U.S. launches in the next two years.
USA